

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Maria A. Glucksmann, et al.

Application No.:

Group No.: N/A

Filed: Herewith

Examiner: N/A

For: 57242, A NOVEL HUMAN G PROTEIN-COUPLED RECEPTOR FAMILY MEMBER AND USES THEREFOR

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (2 pages)
- 3.. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. E1.992152636US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: September 18, 2003

Sean Hunziker
(type or print name of person certifying)

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No.: 09/942,374, filed on August 29, 2001.

The following references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, in the event additional copies are necessary, the undersigned will submit such copies upon request.

September 18, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By 

Kerri Pollard Schray
Registration No. 47,066
75 Sidney Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820

+

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	Herewith
				First Named Inventor	Glucksmann, Maria A., et al.
				Group Art Unit	N/A
				Examiner Name	N/A
Sheet	1	of	1	Attorney Docket Number	MPI00-368P1RCN1M

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(use as many sheets as necessary)</p>				Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td></td> </tr> <tr> <td>Filing Date</td> <td>Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Glucksmann, Maria A., et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>N/A</td> </tr> <tr> <td>Examiner Name</td> <td>N/A</td> </tr> <tr> <td>Attorney Docket Number</td> <td>MPI00-368P1RCN1M</td> </tr> </table>		Application Number		Filing Date	Herewith	First Named Inventor	Glucksmann, Maria A., et al.	Group Art Unit	N/A	Examiner Name	N/A	Attorney Docket Number	MPI00-368P1RCN1M
Application Number																	
Filing Date	Herewith																
First Named Inventor	Glucksmann, Maria A., et al.																
Group Art Unit	N/A																
Examiner Name	N/A																
Attorney Docket Number	MPI00-368P1RCN1M																
Sheet	1	of	1														

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²	
	C1	Database EMBL Online! EMBL: 23 March 2000 (2000-03-23) Muzny D. M., et al.: "Homo sapiens chromosome 12 clone RP11-324E6, WORKING DRAFT SEQUENCE, 8 unordered pieces": Database Accession Number AC026333, XP-002212021 page 42-43		
	C2	Database EMBL Online! EMBL: 02 March 1996 (1996-03-02) Bouillaud F., et al.: "EST52h035 WATM1 Homo sapiens cDNA clone 52h035 similar to gb HSHM74, G protein-coupled receptor family, mRNA sequence.": Database Accession Number N62053, XP-002212022 the whole document		
	C3	Database EMBL Online! EMBL: 16 July 1992 (1992-07-16) Nomura H., et al.: "Human mRNA for HM74": Database Accession Number D10923, XP-002212023 the whole document		
	C4	Database EMBL Online! EMBL: 03 April 2001 (2001-04-03) Wang Y-G., et al.: "Homo sapiens putative chemokine receptor (FKSG80) mRNA, complete cds": Database Accession Number AF345568, XP-002212024 the whole document		
	C5	Nomura et al., International Immunology 5(10):239-249 (1993)		
	C6	Marchese, et al., TiPS 20:370-375 (1999)		
	C7	Stadel et al., TiPS 18:430-437 (1997)		
	C8	Lee, et al., Gene 275:83-91 (2001)		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.